Epygen Biotech
Epygen Biotech is a biopharmaceutical company engaged in research and manufacturing of therapeutic proteins for oncology, cardiovascular, immune disorders, and vaccines. With decades of experience in recombinant protein expression and innovations in protein separation, the company aims to make affordable biologics for patients in the region. It is committed to innovation in biotechnology, developing safe and effective therapies at affordable costs, and contributing to society through social welfare activities.
Industries
Nr. of Employees
small (1-50)
Products
RBD‑based SARS‑CoV‑2 vaccine candidate (antigen)
A receptor‑binding domain (RBD) protein antigen vaccine candidate developed to target SARS‑CoV‑2 variants; reported preclinical high antibody titers and protective efficacy in challenge models. Development funded for Phase I/II clinical trials and intended for large‑scale low‑cost production using a high‑yield filamentous fungal expression platform.
Recombinant streptokinase development program
Collaborative program to develop and scale up production of recombinant streptokinase (thrombolytic protein) for large‑scale manufacture at affordable cost, conducted under collaboration/MOU with research institutes.
RBD‑based SARS‑CoV‑2 vaccine candidate (antigen)
A receptor‑binding domain (RBD) protein antigen vaccine candidate developed to target SARS‑CoV‑2 variants; reported preclinical high antibody titers and protective efficacy in challenge models. Development funded for Phase I/II clinical trials and intended for large‑scale low‑cost production using a high‑yield filamentous fungal expression platform.
Recombinant streptokinase development program
Collaborative program to develop and scale up production of recombinant streptokinase (thrombolytic protein) for large‑scale manufacture at affordable cost, conducted under collaboration/MOU with research institutes.
Services
End‑to‑end biologics CDMO services (clone to vial)
Contract development and manufacturing services covering clone selection, cell banking, upstream and downstream process development, formulation, fill‑finish and release testing for therapeutic proteins and vaccine antigens.
Analytical development and bioassays
Development, qualification and execution of biochemical and cell‑based assays, analytical method development, stability studies and release testing aligned to regulatory guidelines.
Upstream and downstream process scale‑up
Optimization and scale‑up of fermentation and purification processes (stated capability to scale up to 150 L) including TFF, ultrafiltration and multiple chromatography modes.
Aseptic fill‑finish and lyophilization
Aseptic vial filling, lyophilization and packaging of injectable biologics with on‑site QC and controlled storage.
Regulatory and tech‑transfer support
Regulatory strategy guidance for clinical development and manufacturing, preparation of regulatory batches and technology transfer to commercial manufacturers.
End‑to‑end biologics CDMO services (clone to vial)
Contract development and manufacturing services covering clone selection, cell banking, upstream and downstream process development, formulation, fill‑finish and release testing for therapeutic proteins and vaccine antigens.
Analytical development and bioassays
Development, qualification and execution of biochemical and cell‑based assays, analytical method development, stability studies and release testing aligned to regulatory guidelines.
Upstream and downstream process scale‑up
Optimization and scale‑up of fermentation and purification processes (stated capability to scale up to 150 L) including TFF, ultrafiltration and multiple chromatography modes.
Aseptic fill‑finish and lyophilization
Aseptic vial filling, lyophilization and packaging of injectable biologics with on‑site QC and controlled storage.
Regulatory and tech‑transfer support
Regulatory strategy guidance for clinical development and manufacturing, preparation of regulatory batches and technology transfer to commercial manufacturers.
Expertise Areas
- Therapeutic protein development
- Biologics CDMO services (clone-to-vial)
- Vaccine antigen development (RBD-based antigens)
- Bioprocess scale-up and optimization
Key Technologies
- Recombinant protein expression (mammalian, yeast and microbial systems)
- Filamentous fungal high‑yield protein expression platform
- Fermentation and bioreactor scale‑up
- Tangential flow filtration (TFF) and ultrafiltration/diafiltration